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ABSTRACT 
Objective: The nitroxide compound TEMPOL (4-hydroxy-2,2,6,6-tetramethylpiperidine-N-
oxyl radical) has been shown to prevent obesity-induced changes in adipokines in cell and 
animal systems. In this study we investigated whether supplementation with TEMPOL 
inhibits inflammation and atherosclerosis in apoE-/- mice fed a high fat diet (HFD). 
Methods: ApoE-/- mice were fed for 12 weeks on standard chow diet or a high-fat diet. Half 
the mice were supplemented with 10 mg/g TEMPOL in their food. Plasma samples were 
analysed for triglycerides, cholesterol, low- and high-density lipoprotein cholesterol, 
inflammatory cytokines and markers (interleukin-6, IL-6; monocyte-chemotactic protein, 
MCP-1; myeloperoxidase, MPO; serum amyloid A, SAA; adiponectin; leptin). Plaques in the 
aortic sinus were analysed for area, and content of collagen, lipid, macrophages and smooth 
muscle cells. 
Results: High fat feeding resulted in marked increases in body mass and plasma lipid levels. 
Dietary TEMPOL decreased both parameters. In the high-fat-fed mice significant elevations 
in plasma lipid levels and the inflammatory markers IL-6, MCP-1, MPO, SAA were detected, 
along with an increase in leptin and a decrease in adiponectin. TEMPOL supplementation 
reversed these effects. When compared to HFD-fed mice, TEMPOL supplementation 
increased plaque collagen content, decreased lipid content and increased macrophage 
numbers. 
Conclusions: These data indicate that in a well-established model of obesity-associated 
hyperlipidaemia and atherosclerosis, TEMPOL had a significant impact on body mass, 
atherosclerosis, hyperlipidaemia and inflammation. TEMPOL may therefore be of value in 
suppressing obesity, metabolic disorders and increasing atherosclerotic plaque stability.  
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1.  Introduction 
 Dyslipidaemia plays a major role in many cardiovascular disorders including 
atherosclerosis [1]. Total blood cholesterol and LDL-cholesterol (LDL-C) are well-
established independent risk, and graded factors, for cardiovascular disease and meet the 
criteria for causality (reviewed [1]). Multiple mechanisms have been proposed to account for 
the elevated risk associated with increased triglyceride and cholesterol levels, including 
smooth muscle and endothelial damage, increased lipid accumulation in the arterial wall, 
impaired vascular repair, and abnormal plasma lipoprotein content and transport [1]. 
Therapeutic reduction of high-risk lipid fractions are strongly associated with improved 
outcomes, however, prevention and treatment of obesity (by behavioural modification, 
pharmaceuticals or surgical procedures), remain critical to reducing the onset of 
dyslipidaemia and resultant morbidities [1]. Pharmaceuticals also provide tools to investigate 
pathophysiological mechanisms, and one example is the stable nitroxide free radical 
TEMPOL (4-hydroxy-2,2,6,6-tetramethylpiperidine-N-oxyl radical) which has been shown to 
modulate sensitivity to radiation, tumourigenesis and diet-induced body mass gain [2].  
 Nitroxides are stable free radicals with multiple biological effects, including acting as 
protective agents against oxidation in animal models of inflammation (reviewed [3, 4]). 
Whilst the mechanisms involved are not fully understood, it has been shown that nitroxides 
can act: (a) as superoxide dismutase mimetics [5]; (b) as radical scavengers [6-8]); (c) as 
reducing agents for oxidised heme proteins [3, 4, 9-11]; (d) by inhibiting oxidant formation by 
the heme enzyme myeloperoxidase (MPO) [10-12]; and (e) by altering the gut microbiome 
and the accumulation of intestinal tauro-β-muricholic acid which regulates bile acid, lipid and 
glucose metabolism [13].  
TEMPOL (at 10 mg/g of food) has profound inhibitory effects upon body mass gain in 
C3H mice and prevents obesity-induced changes in leptin levels [2]. A similar effect on mass 
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gain has recently been reported for mice fed a high fat diet (HFD) [13]. TEMPOL has also 
been reported to reduce formation of reactive oxygen species induced by diabetes [14], and 
hypertension [15], with the latter effect ascribed to increased nitric oxide (NO˙) production by 
endothelial cells [15] and consequent vasodilation [16]. TEMPOL also protects the 
endothelium in both spontaneously hypertensive rats and small arteries from visceral fat of 
obese subjects [16]. Nitroxides have also been postulated to modulate atherosclerosis and 
vascular inflammation by reducing vascular adhesion molecule-1 (VCAM-1) levels and by 
decreasing the levels and assembly of specific NADPH oxidase-2 (NOX2) subunits [17]. 
In the light of the above data we hypothesised that TEMPOL would modulate 
hyperlipidaemia, inflammation and vascular lipid accumulation in a well-established mouse 




 Animal husbandry of apoE -/- mice (n = 38) was carried out at the National Cancer 
Institute (Bethesda, MD, USA) using female mice purchased from Taconic Farms 
(Germantown, NY, USA). At 9 weeks of age two groups were placed on a bacon-flavoured 
standard diet (SD, AIN-76A) with or without TEMPOL (10 mg/g food; Mitos 
Pharmaceuticals, Newport Beach, CA, USA) supplemented into the food. Food consumption 
by the different groups was similar, and qualitative observations indicated greater activity in 
the TEMPOL-fed groups in line with previous data [2]. The remaining two groups were 
placed on a bacon-flavoured high-fat diet (HFD; 60% fat calories, F1850) with and without 
TEMPOL (10 mg/g food) in the food. Both animal chows were purchased from Bioserv 
(Frenchtown, NJ, USA). All experiments were carried out under the aegis of a protocol 
approved by the National Cancer Institute Animal Care and Use Committee and were in 
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compliance with the Guide for the Care and Use Of Laboratory Animal Resource (2011, 
National Research Council). 
 
2.2 Sample collection and storage 
 Samples were obtained and stored at -80°C until analysed at the Heart Research 
Institute (Sydney, Australia) by a blinded observer, for plasma lipids, cytokines, and 
inflammatory markers. Atherosclerotic lesions in the aortic sinus were processed and analysed 
as previously described [18, 19].	  
	  
2.3 Determination of plasma lipids 
 Total cholesterol and triglycerides were quantified using commercial kits (Wako 
Diagnostics, Osaka, Japan) in plasma diluted 1:5 with Tris-buffered saline. High- and low-
density lipoprotein cholesterol levels (HDL-C and LDL-C respectively) were determined as 
described previously [20, 21]. 
 
2.4 Determination of plasma chemokines, adipokines and inflammatory markers 
 Mouse Quantikine ELISA kits for tumour necrosis factor-alpha (TNF-α), monocyte 
chemotactic protein-1 (MCP-1), leptin and resistin levels were purchased from R & D 
systems (Minneapolis, MN, USA). Other ELISA kits were obtained from the following 
sources: MPO (Hycult Biotech, Inc., Uden, Netherlands); IL-6 (Ray Biotech, Inc., Norcross, 
GA, USA); adiponectin (AssayPro, St. Charles, MO, USA); serum amyloid A (SAA; Tridelta 
Development Ltd., County Kildare, Ireland). Mouse plasma was diluted with the supplied 
diluents as follows: TNF-α (no dilution), MCP-1 (1:2), leptin (1:10), resistin (1:30), MPO 
(1:4), IL-6 (1:6), Adiponectin (1:400), SAA (1:200), with assays carried out according to the 
manufacturer’s guidelines. Data are reported as pg/mL unless indicated otherwise. 
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2.5 Preparation and analysis of aortic sinus tissue  
 Three sets of triplicate cross sections were stained with haematoxylin-eosin and 
photographed as previously [18, 19]. Macrophages (F4/80), smooth muscle cells (alpha-actin) 
and collagen content were quantified by previously published methods at the Heart Research 
Institute (Sydney, Australia) [18, 19]. Lipid levels were assessed as white areas (arising from 
sample delipidation) in images stained with picrosirius red, and were quantified relative to 
plaque area, as described previously [18, 19]. 
 
2.7 Statistical analysis 
 Statistical analyses were undertaken using Prism 5.03 (GraphPad software, San Diego, 
CA, USA) by two-way ANOVA analyses followed by Bonferroni’s post-hoc tests, with 
differences considered statistically significant at p < 0.05, unless otherwise stated. 
 
3. Results 
3.1 Effect of TEMPOL on body mass 
 The body mass of the HFD-fed mice increased at a greater rate over the study period 
than the chow-fed mice (Fig. 1). Inclusion of TEMPOL in the diet significantly reduced this 
gain in mass for the HFD mice to levels similar to those of the chow-fed mice. TEMPOL also 
exhibited a significant effect on the body mass gain of the standard chow-fed mice (Fig. 1); 
however, the extent of the effect was much less than that observed for the HFD. 
 
3.2 Plasma lipids  
Plasma triglyceride, total cholesterol, HDL-C and LDL-C levels were significantly 
elevated in plasma from the HFD- compared to the chow-fed mice (Fig. 1, panels C-F). 
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TEMPOL attenuated this elevation such that the levels detected in the HFD and TEMPOL 
supplemented mice were similar to those of the non-HFD-fed apoE-/- mice. LDL-C levels in 
the chow-fed mice with TEMPOL were elevated over the corresponding animals without 
TEMPOL. The total cholesterol levels in these animals were not however elevated. 
 
3.3 Plasma cytokines 
 MCP-1 levels were not significantly different between the chow- and HFD-fed mice, 
but the MCP-1 levels detected in the HFD-fed mice supplemented with TEMPOL were 
significantly lower than those detected in the HFD-fed mice without TEMPOL (Fig. 2). No 
significant changes were detected in MCP-1 levels between the chow-fed mice with or 
without TEMPOL. IL-6 levels were significantly elevated in the HFD-fed, compared to the 
chow-fed, animals, and this increase was markedly attenuated by TEMPOL (Fig. 2). A similar 
pattern of changes was detected for the inflammatory markers SAA and MPO, with 
TEMPOL-supplementation significantly blunting the increases detected in the HFD-fed, 
compared to chow-fed animals.  
 
3.4 Adipokine profile 
 HFD mice had significantly lower adiponectin levels when compared to chow-fed 
controls (Fig. 3). TEMPOL returned these levels to those detected in the chow-fed and chow-
fed plus TEMPOL animals. Leptin levels showed an inverse pattern, with a significant 
elevation detected in the HFD-fed, compared to chow-fed mice. TEMPOL significantly 
reduced this increase (Fig. 3). The adiponectin and leptin values detected in the HFD-fed mice 
supplemented with TEMPOL were not significantly different to those determined for the 
chow-fed mice. No significant differences in resistin levels were detected between any of the 
groups.  
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3.5 Analysis of atherosclerotic plaques 
 No statistical differences in atherosclerotic plaque area, compared to total area, were 
detected between the chow and HFD-fed mice, though a significant decrease in area was 
detected between the HFD-fed mice supplemented with TEMPOL compared to the chow-fed 
animals supplemented with TEMPOL (Fig. 4). The collagen content of the lesions from the 
HFD-fed mice was significantly lower than that detected in the chow-fed animals, and the 
presence of TEMPOL in the HFD returned these levels to those detected in the chow-fed 
animals without or with TEMPOL supplementation (Fig. 4). There were no differences 
detected in plaque area occupied by α-actin-positive cells though there was a clear trend to 
higher levels in the HFD-fed mice with TEMPOL supplementation compared to its absence 
(Fig. 4). TEMPOL supplementation significantly increased the levels of tissue macrophages, 
as quantified by F4/80 staining (Fig. 5) and decreased the levels of lipid detected in the 
plaques from the HFD-fed mice (Fig. 5).  
 
4. Discussion  
Previous studies have indicated that TEMPOL can act as a protective agent against 
oxidative damage in multiple pathologies (reviewed [3, 4]) and does not to affect cell growth 
or induce toxicity at < 1 mM in cell media [22] or at 10 mg/g food in animal studies (~ 58 
mM) [2, 23]. In the light of this data we investigated whether this compound had therapeutic 
potential against the deleterious effects of a high-fat diet (HFD) in apoE-/- mice, a well-
established model of chronic inflammation and atherosclerosis. 
As expected, feeding with the HFD was accompanied by elevated plasma 
triglycerides, total cholesterol, LDL-C, HDL-C, IL-6, SAA, MPO and leptin, decreased levels 
of adiponectin, and significant atherosclerosis in the aortic sinus. Inclusion of TEMPOL in the 
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animal chow had profound, and in many cases novel, effects on the majority of these 
parameters, indicating that this compound has marked antioxidant, anti-inflammatory and 
anti-hyperlipidaemic effects.  
As observed in previous studies with other mouse strains fed either normal chow [2, 
23] or a HFD [13], TEMPOL had a marked inhibitory effect on the gain in body mass 
associated with HFD feeding. In these previous studies it has been established that TEMPOL 
does not affect food consumption but is associated with increased physical exercise on a 
running wheel [2, 23].  
Of particular interest and novelty are the observations that TEMPOL decreases the 
elevated plasma levels of triglycerides, total cholesterol, LDL- and HDL-cholesterol, leptin, 
MCP-1, IL-6, SAA and MPO, and increases the adiponectin levels detected in the apoE-/- 
mice, back to the levels detected in the chow-fed animals. No effect was detected on plasma 
resistin levels. With regard to the atherosclerotic lesions quantified in the aortic sinus, 
TEMPOL did not significantly change the plaque area, but did enhance the collagen and α-
actin content, as well as the area occupied by macrophage cells (as quantified by F4/80 
staining), and decreased the lipid content. These changes in plaque composition have been 
reported to be associated with a more stable lesion phenotype [24]. 
The current data suggest that TEMPOL may induce these changes via multiple 
mechanisms. It has been show that elevated inflammatory markers are present in obesity-
related metabolic complications both in animals and in humans. Higher plasma levels and 
protein expression of TNF-α has been reported in obese humans [25] and animals [26, 27], 
and increased TNF-α levels and iNOS expression are associated with endothelial dysfunction 
in small arteries present in the visceral fat of obese patients [28] these changes, together with 
vascular superoxide radical generation, have been reported to be attenuated by TEMPOL [28]. 
TEMPOL has well documented superoxide dismutase mimetic activity [3-5] which account 
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for the lower levels of vascular superoxide, but it has also been reported that TEMPOL 
modulates the mRNA and protein levels of the p47phox (but not other) subunits of vascular 
NADPH oxidase (NOx2) which generates superoxide, with this resulting in decreased 
inflammation, and a reduced accumulation of neutrophils and MPO [29].  
Neutrophils are present in early atherosclerotic lesions [30, 31] and are known to be a 
major source, together with monocytes, of the MPO present at sites of inflammation, though 
there is also some evidence for MPO release from tissue macrophages [32, 33]. MPO is a 
major source of reactive oxidants within atherosclerotic lesions [32] and there is considerable 
evidence to support a major role for this enzyme and the oxidants that it generates in the 
development of cardiovascular disease [34, 35].  TEMPOL and related nitroxides have been 
shown to directly inhibit oxidant formation by MPO via interactions with the enzymatic cycle 
of the enzyme [10, 11, 36], and this activity is believed to be responsible, at least in part, for 
the inhibition of MPO-mediated inflammation and tissue damage. 	   
The lesion data obtained for the aortic sinus do not correlate directly with the observed 
obesity and dyslipidaemia, with TEMPOL having no effect on lesion area. This is in contrast 
to a recent study [17] where a significant diminution of lesion area was detected in apoE-/- 
mice fed a fructose-rich diet for 8 weeks with TEMPOL present in drinking water for the final 
4 weeks.	  The lack of effect in the current study may reflect differences between these models. 
In particular, the fructose-fed mice did not have elevated total cholesterol (unlike most human 
atherosclerosis and the current study), though triglycerides were elevated [17], furthermore 
this previous study used en face analysis of lesions, rather than plaque size in the aortic sinus, 
as used here.  
The mechanism by which TEMPOL induces changes in plaque composition in the 
HFD mice compared to those without TEMPOL is less clear, with the data indicating 
significantly increased plaque collagen and macrophage levels, a trend towards higher 
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numbers of α-actin positive cells, and a decreased plaque lipid content. This decrease in 
plaque extracellular lipid content may reflect the lower levels of plasma lipids, less advanced 
foam cell formation, and higher lesion macrophage numbers as a result of a decreased extent 
of apoptosis and necrosis of lesion macrophages [37, 38]. The reduction in lipid content and 
the higher collagen (a marker of extracellular matrix content) and α-actin induced by 
TEMPOL, appear to reflect a more stable and less advanced plaque phenotype [24]. Similar 
changes, with lower lipid levels and foam cell numbers, and reduced inflammation, apoptosis 
and necrotic core formation, have been observed in the aortic sinus of apoE-/- mice fed a pro-
atherogenic diet and treated with D-carnosine octylester [39], and in (streptozotocin-induced) 
diabetic apoE-/- supplemented with carnosine [18]. In the latter case decreased plasma 
triglycerides were also detected. A TEMPOL-induced reduction in diet-induced dyslipidaemia 
has been reported previously for lean (LZR) and obsese Zucker rats (OZR) fed a HFD [40], 
and in Fischer 344 rats [41]. 
In addition to direct effects on cells and processes with the vascular wall TEMPOL 
may also affect adipocytes and the gut microbiome. Thus SAA is expressed at high 
concentrations by adipocytes from obese subjects [42], and plasma SAA levels are increased 
in atherosclerosis, diabetes and obesity [43-45]. This is consistent with the current 
observations, where the HFD-fed mice had markedly elevated SAA and leptin, and lower 
adiponectin levels, that were corrected by TEMPOL. Adiponectin exerts strong anti-
inflammatory and athero-protective effects on vascular tissue, and has an insulin-sensitising 
effect on tissues associated with glucose and lipid metabolism [46, 47]. Lower adiponectin 
levels have also been reported in humans with obesity, diabetes and coronary artery disease 
[48], and hyperleptinaemia is common in obese people, and indicative of greater adipose 
tissue reservoirs and excess secretion causing leptin resistance [49]. These data supports the 
hypothesis that TEMPOL targets adipose tissue [50]. TEMPOL has also been shown to 
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modulate the gut microbiome [13] with the accumulation of intestinal tauro-β-muricholic acid 
providing a potential rationale for the effects of TEMPOL, as the former is a farnesoid X 
receptor (FXR) nuclear receptor antagonist involved in the regulation of bile acid, lipid and 
glucose metabolism.  
Overall these data demonstrates that TEMPOL, a well-tolerated nitroxide, can 
modulate the gain in body mass, dyslipidaemia and inflammation detected in apoE-/- mice fed 
a HFD, with this being associated with changes in atherosclerotic plaque composition 
commensurate with a more stable phenotype.  
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Figure Legends 
 
 Fig. 1. Body mass and plasma lipid parameters for apoE-/- mice that were fed either a chow or 
HFD, with or without TEMPOL supplementation. (A) Mean body mass (g) of mice over the 
time course of the study: ❑, apoE-/- mice fed HFD; ■, apoE-/- mice fed HFD plus added 
TEMPOL; ❍, apoE-/- mice fed standard chow; ●, apoE-/- mice fed standard chow plus added 
TEMPOL. Data were compared using the non-parametric Mann-Whitney U-test of 
significance using WinSTAT® for Excel, with comparisons made between HFD vs. HFD 
plus TEMPOL (* p < 0.001) and standard chow vs. standard chow plus TEMPOL († p < 
0.001). Error bars (+ SD) are only shown for the mice fed HFD, and HFD plus added 
TEMPOL; in some cases these are smaller than the symbols. Panel (B), plasma triglycerides; 
(C) total cholesterol; (D) HDL-cholesterol; (E) LDL-cholesterol. Data in (C)-(E) are given as 
mmol/L. For panels (B) – (E) values are expressed as mean ± SEM and * indicates statistical 
difference against the chow-fed group, + versus the chow-fed group administered TEMPOL, 
and # versus the HFD-fed mice using two-way ANOVA analysis followed by Bonferroni’s 
post-hoc test.  
 
Fig. 2. Plasma cytokines and inflammatory agents in apoE-/- mice that were fed either a chow 
or HFD, with or without TEMPOL supplementation. Plasma cytokines; MCP-1 (Panel A) and 
IL-6 (B) and inflammatory agents; SAA (C) and MPO (D) were measured in mice that were 
fed normal chow or a HFD, with or without TEMPOL supplementation. Values are expressed 
as mean ± SEM. * Indicates statistical difference against the chow-fed group, + versus the 
chow-fed group administered TEMPOL, and # versus the HFD-fed mice using two-way 
ANOVA analysis followed by Bonferroni’s post-hoc test.  
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Fig. 3. Plasma levels of (A) adiponectin, (B) leptin, and (C) resistin, in apoE-/- mice fed either 
a chow or HFD, with or without TEMPOL supplementation. Values are expressed as mean ± 
SEM. * Indicates statistical difference against the chow-fed group, and # versus the HFD-fed 
mice using two-way ANOVA analysis followed by Bonferroni’s post-hoc test.  
 
Fig. 4. (A) Plaque area, (B,C) collagen content, and (D) content of α-actin positive cells (each 
expressed as a percentage over the total area) in the aortic sinus in apoE-/- mice that were fed 
either a chow or HFD, with or without TEMPOL supplementation. Representative images of 
atherosclerotic plaques stained for collagen with picrosirius red in sinus cross-sections are 
shown in panel (C) and quantified in panel (B) from animals fed control chow (CTL), control 
chow plus TEMPOL (CTL + T), high-fat diet (HFD) or HDF plus TEMPOL (HFD + T). 
Values are expressed as mean ± SEM. * Indicates statistical difference against the chow-fed 
group, + versus the chow-fed group administered TEMPOL, and # versus the HFD-fed mice 
using two-way ANOVA analysis followed by Bonferroni’s post-hoc test.  
 
Fig. 5. (A,C) Plaque macrophage (F4/80 staining) and (B) lipid content in the aortic sinus in 
apoE-/- mice that were fed either a chow or HFD, with or without TEMPOL supplementation. 
Panel (A) represents representative images of atherosclerotic plaques stained with antibody 
F4/80 to detect macrophages (pink staining); legend as Fig. 4. Quantification of macrophage 
staining is expressed relative to plaque area in panel (B). Lipid levels were assessed as white 
areas (arising from sample delipidation) in images stained with picrosirius red (cf. Fig. 4) and 
are quantified relative to plaque area in panel (C). Values are expressed as mean ± SEM. * 
Indicates statistical difference against the chow-fed group, + versus the chow-fed group 
administered TEMPOL, and # versus the HFD-fed mice using two-way ANOVA analysis 
followed by Bonferroni’s post-hoc test.  
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